Saturday, November 14, 2015 11:37:20 AM
I truly believe what we experienced from 10/2 until a week ago was a short squeeze or run opposite sentiment since the reversal that day.
Algos and those behind them wipe out all protection etc. what fundamentally changed for the markets that had them reverse. Nothing, negative earnings growth with worse negative revenue growth.
Now the market also has to deal with high alert terrorism risk based on the awful stuff that transpired in Paris post the close.
To sum it up I think the market looked very shaky even before what occurred in Paris so stocks will be under pressure.
That doesn't mean everything is going down because the central banks are in charge until they aren't.
The good news here is we are in November and sometime in Q1 we should have either a positive or negative catalyst.
If positive, I only hope the sentiment is good enough that the market cares.
Algos and those behind them wipe out all protection etc. what fundamentally changed for the markets that had them reverse. Nothing, negative earnings growth with worse negative revenue growth.
Now the market also has to deal with high alert terrorism risk based on the awful stuff that transpired in Paris post the close.
To sum it up I think the market looked very shaky even before what occurred in Paris so stocks will be under pressure.
That doesn't mean everything is going down because the central banks are in charge until they aren't.
The good news here is we are in November and sometime in Q1 we should have either a positive or negative catalyst.
If positive, I only hope the sentiment is good enough that the market cares.
Recent TNXP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:48:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:46:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:40 PM
- Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026 • GlobeNewswire Inc. • 05/14/2026 11:00:00 AM
- Tonix Pharmaceuticals to Participate in Two Investor Conferences in May • GlobeNewswire Inc. • 05/12/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 09:17:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 09:15:25 PM
- Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights • GlobeNewswire Inc. • 05/11/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 09:20:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:05:40 AM
- Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 08:57:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:28 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at J • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 11:11:37 AM
- Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 04/23/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:05:34 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/31/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 11:00:28 AM
- Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain • GlobeNewswire Inc. • 03/26/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/23/2026 08:32:42 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 09:12:47 PM
